Drug Profile


Alternative Names: AAV1 vectored follistatin gene therapy - Milo Biotechnology; AAV1-Follistatin; Gene therapy-delivered myostatin inhibitor (AAV1-FS344) – Milo Biotechnology; rAAV1 CMV huFollistatin 344; rAAV1.CMV.huFollistin344

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Milo Biotechnology; Nationwide Children's Hospital
  • Class Gene therapies
  • Mechanism of Action Follistatin stimulants; Gene transference; Myostatin inhibitors; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Inclusion body myositis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Duchenne muscular dystrophy; Inclusion body myositis

Most Recent Events

  • 01 Nov 2017 Milo Biotechnology completes a phase I/II trial for Duchenne muscular dystrophy (In children, In adolescents, In adults, In the elderly) in USA (IM) (NCT02354781)
  • 12 Oct 2017 Phase-I/II development in Becker muscular dystrophy and Duchenne muscular dystrophy is ongoing in USA (IM) (Milo Biotechnology pipeline, October 2017)
  • 08 Sep 2017 Phase I/II development in Inclusion body myositis is ongoing in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top